Mirum Pharmaceuticals (MIRM) falls 14.81% after hours on Q2 earnings miss and regulatory delay
ByAinvest Wire
Wednesday, Aug 5, 2026 4:32 pm ET1min read
MIRM--
Mirum Pharmaceuticals (MIRM) shares fell 14.81% in after-hours trading following the company's Q2 2026 earnings report. The decline was driven by a GAAP EPS miss of -$1.06 against estimates. Additionally, the FDA recommended a Phase 3 study for Volixibat, delaying the NDA submission to H1 2027, which outweighed a revenue beat and raised full-year guidance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
LEGAL
Privacy PolicyTerms of UseAIME Terms of UseBrokerage DisclaimerAI Risk DisclosuresEditorial PolicyCONTACT US
Email: support@ainvest.com, editorial@ainvest.com, corrections@ainvest.com, press@ainvest.com, legal@ainvest.com
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet